Nifedipine

DRUG INFORMATION

  ADULT
    - Therapy for either hypertension or angina should be initiated with 30 or 60 mg
      once daily.
      Source: US FDA label for nifedipine (Nifedipine), section 'dosage and
      administration', retrieved 2026-08-29
    - Titration to doses above 120 mg are not recommended.
      Source: US FDA label for nifedipine (Nifedipine), section 'dosage and
      administration', retrieved 2026-08-29
    - Angina patients controlled on nifedipine capsules alone or in combination with
      other antianginal medications may be safely switched to nifedipine extended-
      release tablets, USP at the nearest equivalent total daily dose (e.g., 30 mg
      t.i.d. of nifedipine capsules may be changed to 90 mg once daily of nifedipine
      extended-release tablets, USP).
      Source: US FDA label for nifedipine (Nifedipine), section 'dosage and
      administration', retrieved 2026-08-29

  CHILD
    - Safety and effectiveness in pediatric patients have not been established.
      Source: US FDA label for nifedipine (Nifedipine), section 'pediatric use',
      retrieved 2026-08-29

  RENAL IMPAIRMENT
    - No kidney-impairment dose in this label. Not a statement that none is needed.
      Source: Read and found silent: the US FDA label for nifedipine (Nifedipine),
      retrieved 2026-08-29

  HEPATIC IMPAIRMENT
    - No liver-impairment dose in this label. Not a statement that none is needed.
      Source: Read and found silent: the US FDA label for nifedipine (Nifedipine),
      retrieved 2026-08-29

  PREGNANCY
    - Nifedipine has been shown to produce teratogenic findings in rats and rabbits,
      including digital anomalies similar to those reported for phenytoin.
      Source: US FDA label for nifedipine (Nifedipine), section 'pregnancy', retrieved
      2026-08-29
    - Digital anomalies have been reported to occur with other members of the
      dihydropyridine class and are possibly a result of compromised uterine blood flow.
      Source: US FDA label for nifedipine (Nifedipine), section 'pregnancy', retrieved
      2026-08-29
    - Nifedipine administration was associated with a variety of embryotoxic,
      placentotoxic, and fetotoxic effects, including stunted fetuses (rats, mice,
      rabbits), rib deformities (mice), cleft palate (mice), small placentas and
      underdeveloped chorionic villi (monkeys), embryonic and fetal deaths (rats, mice,
      rabbits), and prolonged pregnancy/decreased neonatal survival (rats; not evaluated
      in other species).
      Source: US FDA label for nifedipine (Nifedipine), section 'pregnancy', retrieved
      2026-08-29

  BREASTFEEDING
    - Nifedipine is transferred through breast milk.
      Source: US FDA label for nifedipine (Nifedipine), section 'nursing mothers',
      retrieved 2026-08-29
    - Nifedipine extended-release tablets should be used during breast-feeding only if
      the potential benefit justifies the potential risk.
      Source: US FDA label for nifedipine (Nifedipine), section 'nursing mothers',
      retrieved 2026-08-29